The safety and efficacy of microwave ablation in the treatment of lung cancer: A clinical analysis of single center
10.7507/1007-4848.202103061
- VernacularTitle:微波消融治疗肺恶性肿瘤安全性及疗效的单中心临床分析
- Author:
Haohuan TANG
1
,
2
;
Qi ZHOU
1
,
2
;
Feihu SUN
1
,
2
;
Wei DING
1
,
2
;
Lei SUN
1
,
2
;
Weitao WANG
1
,
2
;
Ping XU
1
,
2
;
Chen FAN
1
,
2
;
Weidong WANG
1
,
2
Author Information
1. epartment of Intervention, Affiliated Wuxi People'
2. s Hospital of Nanjing Medical University, Wuxi, 214023, Jiangsu, P.R.China
- Publication Type:Journal Article
- Keywords:
Microwave ablation;
lung cancer;
safety;
efficacy;
intervention therapy
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2021;28(11):1310-1314
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of microwave ablation (MWA) in the treatment of lung tumors. Methods The clinical data of 31 patients with lung neoplasms treated with MWA from January 2019 to August 2020 in a single center were retrospectively analyzed. There were 17 males and 14 females at an age of 63.4±10.4 years. The characteristics of the lesions, technical success rate, technical efficiency, local progression rate, adverse reactions and complications were recorded in detail. Results There were 39 target lesions with an average diameter of 20.2±10.6 mm. A total of 36 MWA procedures were completed. The initial technical success rate was 84.6% (33/39), and the technical efficiency was 92.3% (36/39). The median postprocedure hospital stay was 2.0 (2.0, 3.0) d. A total of 12.9% (4/31) of the patients had local progression, and the local control rate was 87.1%. The main adverse reactions were pain (12/36, 33.3%), cough (6/36, 16.7%), post-ablation syndrome (6/36, 16.7%) and pleural effusion (3/36, 8.3%). The main complications were pneumothorax (11/36, 30.6%), hemorrhage (8/36, 22.2%), cavitation (2/36, 5.6%) and pulmonary infection (1/36, 2.8%). The median follow-up time was 13.0 (8.0, 18.0) months. No patient died during the follow-up. Conclusion MWA is safe and effective in the treatment of lung tumors with controllable complications. Successive researches with large sample, and medium and long-term follow-ups are needed to explore the significance of combined therapies.
